July 30, 2021 - ROSEN LOGO.jpg
ORPH FINAL DEADLINE ALERT: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Orphazyme A/S Investors with Losses to Secure Counsel Before Important September 7 Deadline in Securities Class Action – ORPH
September 05, 2021 13:15 ET | The Rosen Law Firm PA
NEW YORK, Sept. 05, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or...
July 30, 2021 - ROSEN LOGO.jpg
ORPH BREAKING ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Orphazyme A/S Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ORPH
August 24, 2021 17:45 ET | The Rosen Law Firm PA
NEW YORK, Aug. 24, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or...
logo.png
Orphazyme initiates rolling submission of New Drug Application for arimoclomol with US FDA in Niemann-Pick disease Type C
May 29, 2020 01:12 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcement                                                                                       No....
logo.png
Orphazyme announces US Early Access Program for Niemann-Pick disease Type C
January 06, 2020 08:00 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcement                                                                                       No....
logo.png
Orphazyme reports positive arimoclomol data from open-label phase 2/3 extension in Niemann-Pick disease Type C
January 03, 2020 01:00 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcement                                                                                       No....
logo.png
Orphazyme receives Breakthrough Therapy Designation for arimoclomol in Niemann-Pick Disease Type C (NPC)
November 19, 2019 01:00 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcement                                                                              No....
logo.png
Orphazyme to prepare for filing of arimoclomol in US for Niemann-Pick disease Type C (NPC)
July 21, 2019 06:03 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcement                                                                                                                   No. 18/2019Company Registration No. 32266355      ...
logo.png
Orphazyme to prepare for filing of arimoclomol in Europe for Niemann-Pick disease Type C (NPC)
June 07, 2019 00:56 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcement                                                                                                                   No....
logo.png
Orphazyme reports positive results from full data set of Phase II/III arimoclomol trial in Niemann-Pick disease Type C (NPC)
January 30, 2019 01:14 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcement                                                                                                                   No....
logo.png
Orphazyme reports encouraging arimoclomol clinical trial top-line data in Niemann-Pick disease Type C (NPC)
September 28, 2018 01:00 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcement                                                                                                                   No....